Tag Archives: Soligenix

A Director at Soligenix (NASDAQ: SNGX) is Buying Shares

Today, a Director at Soligenix (SNGX – Research Report), Jerome Zeldis, bought shares of SNGX for $3,720. Following this transaction Jerome Zeldis’ holding in the company was increased by 23.64% to a total of $20.08K. See today’s analyst top recommended

Maxim Group Keeps Their Buy Rating on Soligenix (SNGX)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Soligenix (SNGX – Research Report), with a price target of $4. The company’s shares closed last Monday at $1.10. McCarthy observed: “Soligenix announced that the

Soligenix (SNGX) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Soligenix (SNGX – Research Report) yesterday and set a price target of $4. The company’s shares closed yesterday at $0.83, close to its 52-week low of $0.65. McCarthy commented: “Soligenix

The COB, CEO & Pres of Soligenix (NASDAQ: SNGX) is Buying Shares

Today, the COB, CEO & Pres of Soligenix (SNGX – Research Report), Christopher Schaber, bought shares of SNGX for $3,550. Following this transaction Christopher Schaber’s holding in the company was increased by 13.4% to a total of $33.44K. In addition

Maxim Group Keeps a Buy Rating on Soligenix (SNGX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Soligenix (NASDAQ: SNGX) today and set a price target of $4. The company’s shares opened today at $1.57. McCarthy observed: “Soligenix announced that lead clinical candidate SGX942 (dusquetide) for oral

Soligenix Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Soligenix (NASDAQ: SNGX) today and set a price target of $5. The company’s shares closed on Friday at $1.57, close to its 52-week low of $1.45. McCarthy commented: “Soligenix will